dual EGFR/HER2 inhibitors (Peking University/Beijing University of Chemical Technology/Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University)

N/A

Report date: 2025/03/19 09:03:21
NME

Base Information

Drug Namedual EGFR/HER2 inhibitors (Peking University/Beijing University of Chemical Technology/Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsLung Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesPeking University
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Hospital Of Traditional Chinese Medicine Affiliated With Capital Medical UniversityBeijing University Of Chemical TechnologyPeking University
Inactive CompaniesN/A
Active IndicationsLung Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A